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Triple-negative breast cancer (TNBC) is a highly
aggressive form of breast cancer that exhibits ex-
tremely high levels of genetic complexity and yet a
relatively uniform transcriptional program. We postu-
late that TNBCmight be highly dependent on uninter-
rupted transcription of a key set of genes within this
gene expression program and might therefore be
exceptionally sensitive to inhibitors of transcription.
Utilizing kinase inhibitors and CRISPR/Cas9-medi-
ated gene editing, we show here that triple-negative
but not hormone receptor-positivebreast cancer cells
are exceptionally dependent on CDK7, a transcrip-
tional cyclin-dependent kinase. TNBCcells are unique
in their dependence on this transcriptional CDK and
suffer apoptotic cell death upon CDK7 inhibition. An
‘‘Achilles cluster’’ of TNBC-specific genes is espe-
cially sensitive toCDK7 inhibitionand frequently asso-
ciatedwith super-enhancers.We conclude that CDK7
mediates transcriptional addiction to a vital cluster of
genes in TNBC and CDK7 inhibition may be a useful
therapy for this challenging cancer.
INTRODUCTION
Recent advances in genomic sequencing have led to an unprec-
edented understanding of the genetics of tumor heterogeneity
(Fisher et al., 2013). For a number of cancers, this has led to
the discovery of ‘‘driver’’ oncogenes such as mutant BRAF,
EGFR, and EML4-ALK, which has informed rational drug devel-
opment strategies (Chin et al., 2011). For other tumors, however,
sequencing has only revealed a striking level of heterogeneity
and has not resulted in the identification of clear driver mutations
(Cancer Genome Atlas Research Network, 2011, 2012). Despite
this genetic heterogeneity, a number of these tumors can be
readily identified based upon their gene expression programs174 Cell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc.(Hoadley et al., 2014). We hypothesized that, despite the genetic
heterogeneity, maintenance of these uniform gene expression
programs might require continuous active transcription and
therefore be more sensitive to drugs that target transcription.
We evaluated this hypothesis in the context of triple-negative
breast cancer (TNBC) because this subtype is characterized by
high genetic complexity (Abramson et al., 2015; Cancer Genome
Atlas Network, 2012) and has a characteristic gene expression
program (Parker et al., 2009; Perou et al., 2000). Compared to
hormone receptor (estrogen and/or progesterone receptor)-pos-
itive (ER/PR+) breast cancer, TNBC demonstrates a higher level
of genetic complexity, as indicated by a higher rate of point mu-
tation, gene amplification, and deletion (Cancer Genome Atlas
Network, 2012). Notably, TNBC lacks a common genetic alter-
ation except mutations of tumor suppressor genes such as
INPP4B, PTEN, and TP53 (Abramson et al., 2015; Andre et al.,
2009; Cancer Genome Atlas Network, 2012; Gewinner et al.,
2009; Shah et al., 2012), a situation that has limited the develop-
ment of ‘‘targeted’’ therapies. The highly aggressive nature of
TNBC and the lack of effective therapeutics make this disease
a high priority for discovery biology efforts.
Targeting gene transcription for cancer therapy has long been
considered difficult, due to a presumably universal role of tran-
scription in non-malignant cells or tissues, and consequently,
pharmacologic inhibition of general transcriptional machinery
might lack selectivity for cancer cells and cause intolerable
toxicity. Recent studies, however, have challenged this para-
digm and found that transcription of certain genes is dispropor-
tionately sensitive to inhibition of transcription (Dawson et al.,
2011; Delmore et al., 2011; Chapuy et al.; 2013; Chipumuro
et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014;
Zuber et al., 2011). Those genes, often encoding oncogenic
drivers with short mRNA and protein half-lives (e.g., MYC,
MYCN, and RUNX1), have a striking dependence on continuous
active transcription, thereby allowing for highly selective effects
before ‘‘global’’ downregulation of transcription is achieved.
The continuous active transcription of these genes in cancer
cells is often driven by exceptionally large clustered enhancer
regions, called super-enhancers, that are densely occupied by
transcription factors and co-factors (Hnisz et al., 2013, 2015;
Love´n et al., 2013).
Thecontrol of gene transcription involves a set of cyclin-depen-
dent kinases (CDKs), including CDK7, CDK8, CDK9, CDK12, and
CDK13, that play essential roles in transcription initiation
and elongation by phosphorylating RNA polymerase II (RNAPII)
and other components of the transcription apparatus (Akhtar
et al., 2009; Larochelle et al., 2012; Zhou et al., 2012).We recently
discovered a selective CDK7 inhibitor, THZ1, that covalently
binds to CDK7 and suppresses its kinase activity with an unantic-
ipated level of selectivity based upon modification of a unique
cysteine residue (Kwiatkowski et al., 2014). We further identified
a therapeutic effect of CDK7 inhibition in several types of cancer,
including MYCN-amplified neuroblastoma, small-cell lung can-
cer, and T cell acute lymphoblastic leukemia (Chipumuro et al.,
2014; Christensen et al., 2014; Kwiatkowski et al., 2014). Here,
we report that TNBC demonstrates a profound dependence on
CDK7. We further identified an ‘‘Achilles cluster’’ of TNBC genes
that require CDK7 to maintain expression and that apparently
mediate the extreme sensitivity of TNBC to CDK7 inhibition.
RESULTS
Exceptional Sensitivity of TNBC Cells to Covalent
Inhibition of CDK7
To investigate whether the proliferation of TNBC cells is sensitive
to CDK7 inhibition, we treated triple-negative or ER/PR+ breast
cancer cell lines with increasing concentrations of THZ1. While
ER/PR+ cells were largely unaffected by treatment of THZ1 at
micromolar doses, triple-negative breast cancer cellswere highly
sensitive toCDK7 inhibition, with cell proliferation effectively sup-
pressed by low nanomolar concentrations of THZ1 (IC50 < 70 nM)
(Figures 1A and 1B). In contrast to the extreme sensitivity to
THZ1, TNBC cells weremore resistant to a non-cysteine reactive
analog of THZ1 (THZ1-R) (Kwiatkowski et al., 2014) (Figure S1A),
suggesting that the unique characteristic of THZ1 in covalently
binding to its target determines its antiproliferative potency.
To understand the mechanism underlying the highly selective
effect of THZ1, we next proceeded to test whether CDK7 is
equally inhibited in both triple-negative and ER/PR+ breast can-
cer cells. CDK7 is implicated in regulating the phosphorylation of
the carboxyl-terminal domain (CTD) of RNAPII at multiple sites
(Ser 2, 5, and 7) either directly or via phosphorylating and acti-
vating other CDKs (Akhtar et al., 2009; Glover-Cutter et al.,
2009; Larochelle et al., 2012; Zhou et al., 2012). We exposed
cells to increasing doses of THZ1 or THZ1-R and found that, in
both triple-negative and ER/PR+ breast cancer cells, CTD phos-
phorylation at S2, S5, and S7 was effectively suppressed by
THZ1 but not the inactive THZ1-R (Figures 1C and S1B). The
similar effects on CTD phosphorylation by THZ1 indicates that
CDK7 is similarly targeted in both drug-sensitive and -resistant
cells; thus, TNBC cells appear to be far more dependent on
the activity of CDK7 than ER/PR+ breast cancer cells.
We further found that CDK7 inhibition efficiently induced
apoptotic cell death in TNBC cells, indicated by the induced
cleavage of PARP and Caspase 3 (Figure 1D). In line with the
differential response to CDK7 inhibition, cell death was not
observed in ER/PR+ breast cancer cells treated with THZ1 (Fig-ure 1D). Consistent with previous studies, THZ1 treatment also
failed to induce cell death in non-transformed human cell lines
(BJ fibroblasts and retinal pigment epithelial cells, RPE-1)
(Figure 1D) (Kwiatkowski et al., 2014). Notably, RNAPII CTD
phosphorylation was suppressed by THZ1 in all of these cell lines
(Figure 1D) and thus did not correlate with the cell fate, again indi-
cating an exceptional dependence onCDK7-regulated pathways
in TNBC cells.
In addition to regulating RNAPII CTD phosphorylation, CDK7 is
a component of CDK-activating kinase (CAK), which is thought
to phosphorylate and activate all CDKs, including cell-cycle
CDKs (Schachter and Fisher, 2013). Indeed, CDK7 has been
implicated in phosphorylating CDK1 and regulating mitosis (Lar-
ochelle et al., 2007), and THZ1 treatment has been shown to
induce a G2/M arrest in neuroblastoma cells with MYCN ampli-
fication (Chipumuro et al., 2014). Surprisingly, THZ1 treatment
did not alter the cell cycle in TNBC cells (Figure S1C). To further
investigate whether mitosis is impaired by CDK7 inhibition, we
utilized live-cell imaging to observe the progression of mitosis.
We found that mitosis of TNBC cells (MDA-MB-468) progressed
normally in the presence of THZ1 (Figure S1D and Movie S1 and
S2). The duration of time from nuclear envelope breakdown
(NEBD) to anaphase onset was not significantly changed by
THZ1 treatment (Figure S1E). Despite a lack of mitotic arrest
by THZ1, cell death was efficiently induced (Figures S1D and
S1F and Movie S1). Therefore, the sensitivity of TNBC cells to
CDK7 inhibition is likely not derived from a role of CDK7 in
directly regulating cell-cycle-related CDKs.
Next, we investigated whether the anti-proliferative effects
displayed by THZ1 in established TNBC cell lines would translate
to primary TNBC samples. To address this, we performed pri-
mary culture of tumor cells from patient-derived xenografts
(PDX) of TNBC and treated these cells with THZ1. In three inde-
pendent patient-derived TNBC cultures, THZ1 effectively re-
duced cell viability (IC50 < 100 nM) (Figure 1E). Consistent with
our findings obtained from established cancer cell lines, we
observed that two ER/PR+ primary cultures were largely insensi-
tive to THZ1 (Figures 1E and 1F). Furthermore, treatment of
primary TNBC cells with THZ1 led to suppressed RNAPII
CTD phosphorylation and induction of apoptotic cell death
(Figure 1G). Given that the primary samples were derived from
patients with TNBCwho had progressed onmultiple lines of che-
motherapies, our data indicate that CDK7 inhibition may provide
an effective therapeutic option for patients with this aggressive
disease.
An Analog of THZ1 with Improved Pharmacokinetics
Despite the high anti-proliferative potency of THZ1 in primary
TNBC cells, the stability of THZ1 in vivo (T1/2 of 45 min in mouse
plasma) limits its utility for in vivo investigations. We therefore
modified the structure of THZ1 by altering the regiochemistry
of the acrylamide on THZ1 from 4-acrylamide-benzamide to
3-acrylamide-benzamide, giving rise to an analog THZ2 (Fig-
ure 2A). THZ2 had significantly improved pharmacokinetic fea-
tures, with a 5-fold improved half-life in vivo (Figure 2B). Similar
to THZ1, THZ2 selectively targeted CDK7 (Figure 2C and Table
S1) and potently inhibited the growth of triple-negative, but not
ER/PR+, breast cancer cells (Figures 2D and 2E). THZ2 at lowCell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc. 175
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Figure 1. CDK7 Inhibition Selectively Targets TNBC Cells
(A) Cell growth curves of triple-negative (red) and ER/PR+ (blue) breast cancer cell lines. Cells were treated with increasing concentrations of THZ1 for 48 hr. Cells
were then fixed and stained for the quantification of cell growth. Data are presented as means ± SD.
(B) Bright-field images of cells that were treated with vehicle control or THZ1 (40 nM) for 7 days. Note that THZ1 induced cell death in triple-negative, but not ER/
PR+, breast cancer cells.
(C) THZ1 inhibits RNAPII CTD phosphorylation in both triple-negative (MDA-MB-468) and ER/PR+ (ZR-75-1) breast cancer cells. Cells were treated with vehicle
control (first lane) or increasing concentrations of indicated drug (2, 10, 50, 250, 1,250, and 6,250 nM) for 4 hr before lysates were prepared for immunoblotting.
(D) Immunoblotting analysis of lysates harvested from cells treated for 24 hr with vehicle control or THZ1 (100 nM). Samples in the order of loading were triple
negative (MDA-MB-468, BT549, HCC1187), ER/PR+ (ZR-75-1, T47D) breast cancer cells, and normal human cells (RPE-1, BJ1).
(E) Indicated TNBC (red) or ER/PR+ (blue) primary cultures were treated with increasing concentrations of THZ1. Cells were subjected to CellTiter-Glow
Luminescent Cell Viability Assay after 48 hr of treatment. Data were represented as mean ± SD.
(F) Triple-negative (DFBC12-06) or ER/PR+ (DFBC14-15) primary culture was treatedwith vehicle control or THZ1 (250 nM) for 24 hr. Cells were subjected to LIVE/
DEAD Cell Viability Assay to indicate live (green) and dead (red) cells.
(G) THZ1 inhibits RNAPII CTD phosphorylation and induces apoptosis in primary TNBC cells. Primary TNBC culture (DFBC12-58) was treated with vehicle control
(first lane) or indicated concentrations of THZ1 for 24 hr before lysates were prepared for immunoblotting.
See also Figure S1 and Movies S1 and S2.
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Figure 2. An Analog of THZ1 and the Effect of CDK7 Inhibition on the Growth of Triple-Negative Breast Tumors
(A) Structure of THZ1 and THZ2. The groups of 4-acrylamide-benzamide in THZ1 and 3-acrylamide-benzamide in THZ2 are colored red.
(B) Stability of THZ1 and THZ2 in vivo. Mice were administered by tail vein injection a single dose of THZ1 or THZ2, and blood samples were collected at different
time points. Concentrations of THZ1 and THZ2 in plasma samples were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
approach.
(C) In vitro IC50 for THZ2’s potency in binding to indicated CDK. The LanthaScreen Eu Kinase Binding assay (Invitrogen) was performed with indicated CDKs and
their associated cyclins in the presence of different concentration of THZ2. The IC50 values indicate the affinity of THZ2 toward the ATP binding pocket of CDK.
(D) Cell growth curve of breast cancer cells treated with increasing concentrations of THZ2 for 48 hr. Data are presented as mean ± SD.
(E) Bright-field images of cells treated with vehicle control, THZ2 (370 nM), or THZ1-R (370 nM) for 2 days.
(F) Cell growth curve of indicated TNBC cell lines that were treated with increasing concentrations of THZ2 for 7 days. Upon harvest, cells were fixed and stained
with crystal violet, followed by extraction of the staining for the quantification of proliferation. Data are presented as mean ± SD.
(legend continued on next page)
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nanomolar doses also efficiently suppressed the clonogenic
growth of TNBC cells (IC50 of 10 nM; Figure 2F and S2B).
Like THZ1, THZ2 induced apoptotic cell death in triple-negative,
but not ER/PR+, breast cancer cells or normal human cells (Fig-
ure S2A) and did not cause an obvious alteration in cell cycle
(Figure S2C). Therefore, we have identified an analog of THZ2
with improved pharmacokinetic properties and comparable po-
tency that we elected to use for further investigations.
CDK7 Inhibition Suppresses the Growth of
Triple-Negative Breast Tumors
We proceeded to investigate whether CDK7 inhibitors would ex-
hibit efficacy in vivo. Treating mice intraperitoneally with THZ2
twice daily at the dose of 10 mg/kg did not give rise to overt
toxicity, such as a loss of body weight or behavioral changes
(data not shown). To test whether THZ2 has any therapeutic
effect on triple-negative breast tumors in an orthotopic xenograft
model, we transplanted triple-negative breast tumor cells (MDA-
MB-231) into the mammary fat pads of nude mice. When tumors
reached 200 mm3, mice were treated with vehicle or THZ2
(10 mg/kg). Continuous treatment of THZ2 for 25 days did not
affect body weight (Figure S2D), indicating that THZ2 is well
tolerated in nudemice. The growth rate of tumors in mice treated
with THZ2 was markedly reduced as compared to that of control
tumors (Figure 2G), demonstrating an anti-tumor activity of
THZ2. We also harvested tumors following short-term (50 hr) or
long-term (25 days) treatment and found that both acute and
chronic exposure to THZ2 significantly reduced CTD phosphor-
ylation of RNAPII at all three phosphorylation sites (S2, S5, and
S7; Figures 2H andS2E), indicating that CDK7was efficiently tar-
geted in the tumor cells. Compared to vehicle-treated tumors,
tumor tissues isolated frommice treated with THZ2 had reduced
proliferation and increased apoptosis, as indicated by immuno-
staining against Ki67 and cleaved Caspase 3, respectively (Fig-
ure S2F). Together, these findings indicate that the CDK7 inhib-
itor was able to efficiently reduce tumor cell proliferation and
induce cell death in vivo.
We further evaluated the anti-tumor effect of CDK7 inhibition in
two independent PDX models of triple-negative breast tumors,
DFBC11-26 and DFBC13-11. Both PDX models were estab-
lished from patients with metastatic TNBC, who had progressed
on multiple lines of chemotherapy. Tumor fragments were trans-
planted into the mammary fat pads of NOD-SCID mice. Our first
experiment with THZ2 in NOD-SCID mice led to reduced body
weight, suggesting that THZ2 might be less well-tolerated in(G) Growth of triple-negative breast tumors (MDA-MB-231) in nudemice treated w
are presented; *p < 0.05 (Student’s t test).
(H) Immunoblotting of tumor lysates harvested from nude mice treated with vehicl
last treatment and subjected to the preparation of RIPA lysates. Three independ
(I) Growth of patient-derived triple-negative breast tumors (DFBC11-26) in NOD-S
Mean ± SEM values are presented; **p < 0.01 (Student’s t test).
(J) Growth of patient-derived triple-negative breast tumors (DFBC13-11) in NOD-S
Mean ± SEM values are presented; *p < 0.05 and **p < 0.01 (Student’s t test).
(K) H&E staining of tissue sections (DFBC13-11) indicating tumor regression aft
compared to control. Images on the left and right were captured using 43 and 1
(L) Immunoblotting of tumor lysates (DFBC11-26) harvested frommice treatedwith
for vehicle and THZ1 treated groups, respectively) were loaded in duplicates.
See also Figure S2 and Table S1.
178 Cell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc.this particular mouse strain. We therefore proceeded with using
THZ1 in the PDX model of TNBC. When tumors grew to an
average size of80mm3,micewere treatedwith THZ1. Although
THZ1 has poor pharmacokinetic properties, treating mice with
this drug led to a substantial blockage of tumor growth in both
patient-derived tumor models (Figures 2I and 2J). Notably,
THZ1 treatment resulted in a loss of tumor cellularity and disease
regression (Figures 2J and 2K). Analysis of tumor tissues also
demonstrated markedly decreased CTD phosphorylation of
RNAPII and induced PARP cleavage, an indicator of apoptotic
cell death (Figure 2L). These results indicate that CDK7 inhibition
has potent anti-tumor activity in patient-derived TNBC in vivo.
TNBC Cells Are Highly Dependent on CDK7
To complement the pharmacological studies, which have the
potential for unanticipated ‘‘off-target’’ effects, we first used
short hairpin RNA (shRNA) to decrease expression of CDK7 in
a variety of breast cancer cell lines. Using doxycycline-inducible
shRNA vectors targeting multiple independent sequences of
CDK7, we were able to reduce the abundance of CDK7 protein
by 20%–50% (Figure S3A). This modest reduction in CDK7
abundance was sufficient to inhibit the growth of triple-negative,
but not ER/PR+, breast cancer cells (Figure S3B).
To further corroborate these results, we used the CRISPR/
Cas9 technique to genetically edit the CDK7 gene in five TNBC
cell lines. Treating cells with constructs encoding two indepen-
dent small guiding RNA targeting CDK7 (sg_CDK7) led to a sub-
stantial reduction of CDK7 protein (Figure S3C) and suppression
of cell growth preferentially in triple-negative, but not ER/PR+,
breast cancer cells (Figure 3A). Notably, introducing sg_CDK7
strongly impaired tumor formation from orthothopically trans-
planted TNBC cells (Figure 3B). As observed with the CDK7 in-
hibitor, sg_CDK7 also induced apoptotic cell death in TNBC cells
(Figure 3C) and had little effect on cell-cycle distribution (Figures
3D and S3D). Thus, both shRNA-mediated knockdown of CDK7
and CRISPR/Cas9-mediated CDK7 gene editing produce ef-
fects on TNBC cells that phenocopy pharmacologic inhibition
of CDK7. These results support the view that CDK7 is the phar-
macologically relevant target of the inhibitor and that CDK7 rep-
resents a bona fide target for TNBC.
CDK7 Is a Uniquely Important Transcriptional CDK for
TNBC
CDK7 is one of the transcriptional CDKs that regulate the initi-
ation or elongation of RNAPII-mediated transcription (Zhouith vehicle (n = 8) or THZ2 (n = 7; 10 mg/kg intraperitoneal). Mean ± SEM values
e or THZ2 (10 mg/kg intraperitoneal) for 2 days. Tumors were isolated 3 hr after
ent samples from each treatment were loaded in duplicates.
CID mice treated with vehicle (n = 4) or THZ1 (n = 6; 10 mg/kg intraperitoneal).
CID mice treated with vehicle (n = 6) or THZ1 (n = 5; 10 mg/kg intraperitoneal).
er THZ1 treatment. Note that THZ1-treated tumor shows a loss of cellularity
03 object lens, respectively.
vehicle or THZ1 (10mg/kg intraperitoneal) for 21 days. Samples (two and three
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Figure 3. Loss of CDK7 Impairs TNBC Cell
Growth and Tumorigenesis
(A) Loss of CDK7 in TNBC cells impairs cell viability
and proliferation. The left, middle, and right panels
show the bright-field images, the crystal violet
staining of cells, and the quantification of cell
growth, respectively. Data in the right panel are
presented as mean ± SD; *p < 0.01 and ***p <
0.0001 (Student’s t test).
(B) Tumor volume of xenografts derived from
cells infected with sg_GFP or sg_CDK7 (sg_
CDK7_2 in Figure 3A). Cells were infected with
lentivirus, selected with puromycin for 2 days,
and then harvested for transplantation. Two
million MDA-MB-468 or MDA-MB-231 or 4
million SUM149 cells (viability > 94% for all
groups, assayed by trypan blue exclusion) were
transplanted into mammary fat pads of nude
mice. Tumor volume was measured 4 weeks
after transplantation for the lines of SUM149 and
MDA-MB-231 and 5 weeks for MDA-MB-468.
Data were represented as mean ± SEM, with p
value indicated. The right panel shows immu-
noblotting from cultured cells that were used for
transplantation. Note that the protein abun-
dance of CDK7 was efficiently decreased by
sg_CDK7.
(C) Immunoblotting of lysates from cells intro-
duced with CRISPR constructs. Lentivirus-in-
fected and puromycin-selected cells were seeded
in 6-well plate (20, 000 cells per well) and har-
vested in 4 days. RIPA lysates were subjected to
the analysis of apoptotic cell death (indicated by
PARP and Caspase 3 cleavage).
(D) Cell-cycle analysis of cells infected with lenti-
virus encoding sg_GFP, two independent sgRNA
targeting CDK7. Cells were prepared as in (C) and
then fixed for cell-cycle assay.
See also Figure S3.et al., 2012). The demonstration of CDK7 as a selective target
for TNBC led us to ask if other transcriptional CDKs might
also serve as therapeutic targets. We used CRISPR/Cas9 to
ablate six known CDKs that are implicated in transcriptionalCell 163, 174–186, Seregulation, including CDK7, 8, 9, 12,
13, and 19 (Figures 4A and S4). These
studies demonstrated that, like CDK7,
CDK9 was also required for clonogenic
growth of TNBC cells (MDA-MB-231,
MDA-MB-468, and BT549) (Figures 4B
and 4C). CDK9 has been implicated in
regulating transcriptional elongation,
and physiologically, in the differentiation
of multiple cell types (Shapiro, 2006).
To determine whether CDK9 can also
be targeted for TNBC in a selective
manner, we further ablated transcrip-
tional CDKs in ER/PR+ breast cancer
line (ZR-75-1) (Figure S4). Notably, ER/
PR+ breast cancer cells were also
sensitive to sg_CDK9 but were largely
unaffected by sg_CDK7 (Figures 4C and 4D). Together, these
data suggest that, among these transcriptional CDKs, CDK7
is uniquely required for the survival and proliferation of
TNBC cells.ptember 24, 2015 ª2015 Elsevier Inc. 179
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(A) Immunoblotting of lysates from MDA-MB-468
cells that were infected with lentivirus encoding
Cas9 and sgRNA targeting GFP or individual tran-
scriptional CDK. The asterisk (*) denotes a non-
specific signal for anti-CDK13.
(B) Role of transcriptional CDK for the indicated
TNBC cells. After infection and selection with
puromycin (1.5 mg/ml, 48 hr), cells were seeded in
12-well plate (5000 per well for MDA-MB-468,
10,000 per well for BT549). Cells were fixed after
11 days and stained with crystal violet.
(C) Quantification of cell proliferation. Cells were
treated as in (B). The staining was subsequently
extracted for measurement of absorbance to
quantify cell growth. Data are presented as mean ±
SD; *p < 0.0001 (Student’s t test).
(D) Bright-field images of cells infected with virus
encoding sg_GFP, sg_CDK7 or sg_CDK9. Cells
were assayed as in (B) and imaged with an inverted
microscope.
See also Figure S4.CDK7-Dependent Transcription of an ‘‘Achilles Cluster’’
of TNBC Genes
Given the role of CDK7 in phosphorylating the RNAPII CTD and
CDK9 at active genes (Drapkin et al., 1996; Glover-Cutter
et al., 2009; Akhtar et al., 2009; Larochelle et al., 2012; Kwiat-
kowski et al., 2014), we expected that CDK7 inhibition would
disrupt gene expression. Indeed, THZ1 treatment led to a
dose-dependent reduction in steady-state mRNA levels for the
tested breast cancer cell lines (Figures 5A and S5A). However,
THZ1 treatment affected the proliferation of triple-negative, but
not ER/PR+, breast cancer cells. Previous studies with other
cancer cell types have shown that THZ1 treatment can cause
selective loss of cancer-specific oncogene expression with con-
current loss of tumor cell viability (Kwiatkowski et al., 2014; Chi-
pumuro et al., 2014; Christensen et al., 2014). We therefore hy-
pothesized that a critical set of TNBC genes that are
differentially expressed between TNBC and ER/PR+ cells may
confer the special sensitivity of TNBC cells to CDK7 inhibition.
To test this hypothesis, we first identified genes that are overex-180 Cell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc.pressed in TNBC compared to ER/PR+
breast cancer lines. Genome-wide
expression data were generated from
two TNBC and two ER/PR+ cell lines
over a THZ1 concentration course, and
genes were identified that were overex-
pressed in either TNBC line relative to
the ER/PR+ lines. Approximately 1,000
genes were overexpressed in TNBC lines
relative to ER/PR+ lines; 451 of thesewere
found to be especially sensitive to treat-
ment with THZ1 (greater than 1.5-fold
loss of expression) (Figure 5B).
Gene ontology analysis of the TNBC-
specific and THZ1-sensitive genes
showed that they were significantly en-riched for factors involved in signaling and transcription re-
gulation (Figure 5C). Notably, the genes within these categories
included a substantial number of signaling molecules and
transcription factors with established roles in breast cancer,
including TGFB, STAT, WNT, and EGFR/MET-mediated sig-
naling (Bafico et al., 2004; Brand et al., 2014; Knight et al.,
2013; Lu et al., 2014; Pukrop et al., 2006; Truong et al., 2014;
Yang et al., 2011) (Figure 5D). Additionally, genes encoding tran-
scription factors whose transcription is regulated by these
signaling pathways in breast cancer, including MYC, ETS1,
and the epithelial-to-mesenchymal transition-related transcrip-
tion factors SOX9, TWIST1, and FOXC1, were enriched in
this gene set (Guo et al., 2012; Lu et al., 2014; Scheel et al.,
2011; Taube et al., 2010; Watabe et al., 1998; Xu et al., 2010;
Yang et al., 2004). The majority of these signaling components
and transcription factors were commonly expressed in both
TNBC cell lines and patient-derived primary cells (Tables S2
and S3A). We thus identified genes showing TNBC-specific
expression and sensitivity to THZ1 that encode transcriptional
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regulators and signaling factors, which are candidate mediators
of the response to THZ1. This cluster of vital genes encoding
transcriptional regulators and signaling factors in TNBC cells
may thus collectively represent a TNBC-specific vulnerability—
an ‘‘Achilles cluster’’—for TNBC (Table S3B).
We next sought a mechanistic explanation for the particular
sensitivity of Achilles cluster genes to THZ1 treatment and first
noticed that 40% of the genes in the Achilles cluster were asso-
ciated with super-enhancers in TNBC cells. In comparison, only
11% of all expressed genes are associated with super-en-
hancers in TNBC cells (p = 8.18 3 1020, chi-square test), and
the majority of Achilles cluster genes (83%) are not associated
with super-enhancers in ER/PR+ breast cancer cells (Figures
5E, S5B, and S5C and Table S4). Previous work has shown
that super-enhancers concentrate components of the transcrip-
tional apparatus to drive high-level expression of their target
genes (Hnisz et al., 2013; Love´n et al., 2013; Whyte et al.,
2013). Their extraordinary reliance on transcription regulators,
including CDK7, may confer special sensitivity to transcriptional
inhibitors like THZ1 (Kwiatkowski et al., 2014; Love´n et al., 2013;
Chapuy et al., 2013; Chipumuro et al., 2014). Therefore, we hy-
pothesized that the expression of these super-enhancer-associ-
ated Achilles cluster genesmight bemore sensitive to THZ1 than
other TNBC genes. Indeed, analysis by microarray expression
confirmed that expression of genes associated with super-
enhancers in TNBC is particularly sensitive to THZ1 treatment
(Figure S5D). Super-enhancers also serve as a platform for re-
gulation by multiple signaling pathways, and perturbation of
signaling pathway components can have a profound effect
on super-enhancer-associated genes (Hnisz et al., 2015). The
super-enhancers associated with genes in the Achilles cluster
show a significant enrichment in DNA-binding motifs for ter-
minal effector transcription factors of signaling pathways
(Figure 5F). Taken together, these results suggest that the su-
per-enhancer-driven Achilles cluster genes may be sensitive toFigure 5. Genes Expressed Differentially in TNBC versus ER/PR+ Bre
Cellular Functions for TNBC Survival
(A) THZ1 treatment globally affects steady-state mRNA levels. BT549 and MDA-M
6 hr. Heatmaps display the Log2 fold change in gene expression versus vehicle
(B) Genes differentially expressed between TNBC and ER/PR+ breast cancer lines
PR+ cells for a gene. Genes that were differentially expressed in either of two TNBC
T47D)were identifiedasTNBCspecific (right sideof y axis).Genes thatweredifferen
lineswere identified as ER/PR+ specific (left side of y axis). Geneswhose expressio
for TNBC specific; green for ER/PR+ specific). Log2 fold change between TNBC a
(C) Enriched Gene Ontology functional categories of TNBC-specific genes sensit
shown. Individual bars represent the Bonferroni-corrected p value for enrichment
genes are shown in blue. Values for ER/PR+-specific, THZ1-sensitive genes are
(D) Depiction of signaling pathways and transcription factors that comprise Achi
(E) Achilles cluster genes are enriched in super-enhancers-associated genes.
the Achilles cluster (166) and genes that have TNBC super-enhancers (SE) in eith
* density) in enhancer regions for all stitched enhancers in MDA-MB-468 TNBC ce
Highlighted super-enhancers are associated with selected members of the Achil
(F) Enrichment of DNA-binding motifs targeted by signaling transcription factors in
TNBC cells. The motif bound by the CTCF transcription factor is not enriched in
negative control.
(G) Genes most strongly downregulated by THZ1 treatment in patient-derived TN
analysis of Achilles cluster genes in comparison to genes downregulated in TNBC
with THZ1 (250 nM) for 6 hr. GSEA-supplied p values are given.
See also Figure S5 and Tables S2, S3, and S4.
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connected regulation by signaling pathways whose components
are encoded by genes that are themselves sensitive to THZ1.
We next asked whether THZ1 would induce similar gene
expression changes in primary TNBC cells. Gene set enrichment
analysis indicated that the genes most sensitive to THZ1 in pri-
mary TNBC cells are enriched for the TNBC-specific Achilles
cluster genes (Figure 5G). Indeed, quantitative PCR (qPCR)
confirmed that, in primary TNBC cultures, the expression of
selected TNBC cluster genes was particularly vulnerable to
CDK7 inhibition (Figure S5E).
TNBC Cells Are Addicted to the Expression of Achilles
Cluster Genes
Next, we sought to confirm that components of the Achilles clus-
ter are essential for TNBC cells and are thus likely to contribute to
the cellular response of TNBC cells to CDK7 inhibition. To reflect
the composition of the Achilles cluster, we chose eight candidate
Achilles cluster genes that encode for super-enhancer-associ-
ated transcriptional regulators and signaling factors for this anal-
ysis.We usedCRISPR/Cas9-mediated gene editing to knock out
these candidate genes and assessed how the functional loss of
these genes impacts TNBC proliferation and viability. We found
that triple-negative (MDA-MB-468, BT549) breast cancer cells
were more dependent for proliferation on EGFR, FOSL1,
FOXC1, MYC, and SOX9 than ER/PR+ (ZR-75-1) breast cancer
cells, while proliferation of the TNBC and ER/PR+ cell lines
was similarly sensitive to loss of EN1, ETS1, and TWIST1 (Fig-
ures 6A and S6A). Using additional CRISPR vectors that target
independent sequences of EGFR or SOX9, we confirmed that
gene editing of these two genes suppressed cell growth and
induced apoptotic cell death (Figures 6B, 6C, S6B, and S6C).
EGFR has been pursued as a therapeutic target for TNBC
(Corkery et al., 2009; Ueno and Zhang, 2011). However, kinase
inhibitors of EGFR have not produced satisfactory results inast Cancer Cells and Sensitive to CDK7 Inhibition Indicate Critical
B-468 TNBC cells were treated with THZ1 at the indicated concentrations for
control for the set of expressed transcripts.
. Individual bars represent the difference in expression in TNBC cells versus ER/
cell lines (BT549 andMDA-MB-468) relative to two ER/PR+ lines (ZR-75-1 and
tially expressed in either of twoER/PR+ lines relative to twoTNBCbreast cancer
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nd ER/PR+ expression is shown along the x axis at the bottom of the image.
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(A) CRISPR/Cas9-mediated editing of selected
TNBC Achilles cluster genes in TNBC cell line.
MDA-MB-468 cells were infected with lentivirus
encoding indicated sgRNA, selected with puro-
mycin. (Left) Immunoblotting for the expression of
indicated genes. (Right, top) Cells were seeded in
12-well plates (5,000 cells per well), harvested in
10 days, and stained with crystal violet; the staining
was extracted for the quantification of cell growth
(right bottom). Data were represented as mean ±
SD; *p < 0.001.
(B) Additional CRISPR vectors decrease the
protein abundance of EGFR. Vectors encoding
sg_EGFR_2 and sg_EGFR_3 were tested along
with sg_EGFR_1 (sg_EGFR in Figure 6A). Protein
lysates were harvested for immunoblotting.
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(C) CRISPR/Cas9-mediating gene editing of EGFR
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See also Figure S6.TNBC clinical trials (Carey et al., 2012). We used three indepen-
dent kinase inhibitors that are known to target EGFR (erlotinib,
gefitinib, and lapatinib) and found that EGFR kinase inhibition
largely spared TNBC cells (Figures 6D and S6D), despite evi-
dent suppression of EGFR autophosphorylation and down-
stream MAPK phosphorylation by these inhibitors (Figures 6E
and S6E). These data indicate the existence of kinase-indepen-
dent functions of EGFR that are essential for TNBC cell growth
and survival (Weihua et al., 2008) and further suggest that target-
ing the transcription of EGFR, as achieved by CDK7 inhibition,
provides a unique advantage that cannot be achieved by inhibi-
tors of EGFR kinase activity. Together, these data show that
targeting CDK7-dependent transcription represents an effective
means to collectively suppress the expression of multiple onco-
genes that are critical for the proliferation and viability of TNBC
cells.
DISCUSSION
Triple-negative breast cancer is a highly aggressive subtype of
breast cancer that lacks effective therapeutics, due in part to the
genetic complexity that has limited thedevelopment of ‘‘targeted’’
therapies. Despite its heterogeneous nature, TNBC cells share a
similar transcriptional program, suggesting that tumors of this
subtypemay be highly dependent on expression of at least a sub-
setof theactivegenes in thesecells.We found that TNBCcells are
exceptionally dependent on the transcriptional cyclin-dependentkinase CDK7 and that a cluster of TNBC-specific genes is espe-
cially sensitive to CDK7 inhibition. Our results thus indicate that
CDK7 mediates transcriptional addiction to this vital cluster of
genes inTNBCand thatCDK7 inhibition represents a highly prom-
ising therapy for this subtype of breast cancer.
CDK7 inhibition revealed an ‘‘Achilles cluster’’ of genes in the
TNBC transcriptional program that are likely to be responsible, at
least in part, for rendering these cells selectively sensitive to
THZ1 treatment. These genes were identified by their overex-
pression in TNBC cells relative to ER/PR+ cells, their sensitivity
to THZ1, and their involvement in transcriptional regulation and
in signaling. This group contains putative oncogenes that are
misregulated in the triple-negative disease state and essential
for TNBC tumorigenicity. For example, loss of transcription fac-
tors FOSL1 or SOX9 dramatically impairs the tumorigenic po-
tency of TNBC cells (Tam et al., 2013; Wang et al., 2013) (Figures
6 and S6). Similarly, perturbation of MET- and EGFR-mediated
signaling reduces TNBC cell proliferation (Brand et al., 2014;
Hsu et al., 2014; Sohn et al., 2014; Figures 6 and S6).
A striking number of genes in the TNBC ‘‘Achilles cluster’’ were
associated with super-enhancers in triple-negative, but not in
ER/PR+, breast cancer cells, suggesting a mechanism that
may contribute to their sensitivity to CDK7 inhibition (Chipumuro
et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014).
Transcription of many of these genes is known to be regulated
by signaling pathways whose members are represented in the
cluster, and super-enhancers are thought to serve as a platformCell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc. 183
for regulation of transcription by signaling pathways. Thus, su-
per-enhancers associated with genes in the Achilles cluster
may confer sensitivity to THZ1 by two means: (1) dependency
on high levels of transcription apparatus that includes the imme-
diate target of the drug and (2) dependency on a functionally in-
terconnected network of transcription factors and signaling
components. Other genes in the cluster do not appear to be
associated with super-enhancers, however, so there are likely
to be other reasons for their sensitivity to CDK7 inhibition. For
example, these genes may depend on continuous expression
of some of the super-enhancer-driven transcription factors and
may thus be affected secondarily. It is also possible that tran-
scriptional control of this group is more dependent on CDK7
function than others (Kanin et al., 2007), perhaps because they
cannot utilize alternative pathways of RNA Pol II CTD phosphor-
ylation, such as that enabled by Erk1/2 (Tee et al., 2014).
The ‘‘Achilles cluster’’ of TNBC genes described here repre-
sents a collection of genes encoding transcriptional regulators
and signaling components that are overexpressed in multiple
TNBC cells and sensitive to CDK7 inhibition, which differs from
the well-established approach of seeking a signature for a can-
cer subtype. Signatures typically include genes that are com-
monly expressed in cancer subtypes; such signatures are
especially valuable when it is likely that a common gene or set
of genes must be responsible for a phenotype. In contrast,
when the subtype is genetically heterogeneous, we suggest
that it is valuable to compile a larger collection of genes (the
union of genes in multiple samples, rather than the intersection)
that are affected by transcriptional inhibition in multiple cell lines
or patient samples concurrent with a cellular phenotype because
disregulation of different subsets of the genes in the cluster may
produce the same phenotype in a cancer subtype with a com-
plex genotype. The benefit of this approach is the potential to
explain how tumor cells that are genetically heterogeneous
may be dependent on diverse, yet overlapping, sets of genes.
The strategy of targeting transcription of a cluster of cancer-
specific genes, as described here for TNBC, may be applicable
to other difficult-to-treat cancers. Recent large-scale efforts
have found that TNBC gene expression patterns are highly
correlated with aggressive ovarian cancer and lung squamous
carcinomas (Cancer Genome Atlas Network, 2012; Hoadley
et al., 2014). As with TNBC, these cancers have a high mutation
rate, an extremely high prevalence of p53 mutations, and lack a
commonly altered genetic event that can be targeted for thera-
peutic intervention (Cancer Genome Atlas Research Network,
2011, 2012). Thus, it is possible that various aggressive tumors
develop transcriptional addictions to clusters of genes that are
misregulated and dependent on CDK7, and if so, CDK7 inhibition
might be useful therapy for such cancers.
In summary, we have discovered a CDK7-dependent tran-
scriptional addiction in triple-negative breast cancer and identi-
fied CDK7 inhibition as a highly selective and potent means to
disrupt expression of a key cluster of genes. Our study demon-
strates that inhibition of transcription is an effective strategy to
target highly aggressive breast cancers with high genetic hetero-
geneity and lacking obvious ‘‘driver’’ oncogenes. Further studies
will be required to determine whether these observations will
translate to clinical treatment of human breast cancer.184 Cell 163, 174–186, September 24, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cell Culture
Human breast cancer cell lines were grown in RPMI-1640, 10% fetal bovine
serum, and 1% penicillin/streptomycin. For gene knockdown assays, cells
were infected with lentivirus encoding sgRNA or tetracycline-inducible shRNA.
Details of cell culture, construction of plasmids, and viral infection are
described in the Supplemental Experimental Procedures.
Animal Studies
All animal experiments were conducted in accordance with the animal use
guidelines from the NIH and with protocols approved by the Dana-Farber Can-
cer Institute Animal Care and Use Committee. Full details are described in the
Supplemental Experimental Procedures.
ChIP-Seq and Data Analysis
ChIP was performed as previously described (Lee et al., 2006), using anti-
H3K27ac (Abcam, AB4729A). Details of ChIP-seq and data analysis are
described in the Supplemental Experimental Procedures. ChIP-Seq and
gene expression microarray data are deposited in GEO: GSE69107.
Data Analysis of Gene Expression
To calculate differential expression, Log2 signal intensities were used. For
each transcript, the maximum Log2 signal intensity from either of the two
ER/PR+ breast cancer cell lines was subtracted from the maximum Log2
signal intensity for that transcript in either of the two TNBC cell lines. Tran-
scripts with a difference of +2 or greater were classified as more expressed
in TNBC cells. Transcripts with a difference of 2 or less were classified as
more expressed in ER/PR+ breast cancer cells. For sensitivity to THZ1 treat-
ment, transcripts were considered sensitive if the expression level declined
greater than 1.5-fold upon treatment with 250 nM THZ1. Any gene with one
or more transcripts that passed the two criteria described above was consid-
ered for further analysis. For gene ontology analysis, the DAVID suite of online
tools (http://david.abcc.ncifcrf.gov/tools.jsp) was used to interrogate the mo-
lecular function ontology defined by the Gene Ontology Consortium.
ACCESSION NUMBERS
ChIP-seq and gene expression microarray data are deposited in GEO:
GSE69107.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, four tables, and twomovies and can be foundwith this article online
at http://dx.doi.org/10.1016/j.cell.2015.08.063.
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